In patients with postinfarction sustained ventricular tachycardia showing one or more antiarrhythmic drug failures, the question is how long to proceed with new drug trials before deciding to perform map-guided arrhythmia surgery. Although the techniques of this surgery developed rapidly in the early 1980s, this therapy may be offset by damage to residual left ventricular function. However, surgery has been shown to be very effective in selected groups of patients.
Introduction
Sustained ventricular tachycardia or ventricular fibrillation after the acute phase of myocardial infarction is associated with an unfavourable outcome, particularly in patients with severe left ventricular dysfunction Antiarrhythmic drug therapy will usually be the first step of therapy, but this approach is frequently
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disappointing, and spontaneous recurrences of ventricular tachyarrhythmias require other drug trials 12 " 31 . Currently, surgical ablation of postinfarction ventricular tachycardia guided by intra-operative mapping, yields very acceptable long-term results regarding suppression of ventricular arrhythmias and prevention of sudden death' 4 " 121 , and the in-hospital and long-term survival have substantially improved after application of selection criteria for map-guided arrhythmia surgery 1 ' 31 . After one or more antiarrhythmic drug failures, the question arises whether antiarrhythmic drug therapy should be continued with further drug trials or whether arrhythmia surgery should be undertaken. This question is relevant in view of the previously reported negative correlation between drug efficacy and the number of previously failed antiarrhythmic drug trials 1 ' 4 ' 151 . On the other hand, successful surgical eradication of postinfarction ventricular tachycardia might sometimes be counteracted by unpredicted damage to the residual left ventricular function due to the surgical procedure. To solve this dilemma, a randomized study was conducted comparing the efficacy of continued antiarrhythmic drug therapy vs arrhythmia surgery in patients with recurrent sustained postinfarction ventricular tachycardia or ventricular fibrillation, refractory to one or more antiarrhythmic drugs.
Methods

Patient selection
Patients with sustained ventricular tachycardia, ventricular fibrillation, or aborted arrhythmic death emerging beyond the acute phase of myocardial infarction were studied. These patients were primarily admitted or referred for cardiac surgery or antiarrhythmic drug testing. Prior to this study, at least one failure of antiarrhythmic drug treatment had occurred in all patients.
Inclusion criteria were: (1) eligibility for mapguided surgery based on the previously described left ventricular function score, visualized by standard left ventricular angiography in both oblique projections (Presence of at least three out of nine segments of the left ventricle showing normal contraction was a prerequisite for direct arrhythmia surgery); (2) electrocardiographic (ECG) documentation of ventricular tachycardia or ventricular fibrillation, and in cases of aborted arrhythmic death without arrhythmia recording, inducibility of sustained ventricular tachycardia or ventricular fibrillation with programmed electrical stimulation.
Exclusion criteria were: (1) clear reasons for cardiac surgery, such as severe angina, symptomatic three-vessel coronary artery disease and manifest heart failure beyond the arrhythmic events; (2) previous cardiac surgery; (3) poor residual left ventricular function after myocardial infarction; (4) arrhythmia surgery necessary for 'end stage' antiarrhythmic drug therapy according to the cardiologist.
Randomization and treatment
After inclusion and informed consent, patients were randomized for antiarrhythmic drug treatment or mapguided arrhythmia surgery. After randomization in the drug limb, testing of either sotalol, flecainide or propafenone was started immediately and evaluation of the therapeutic results was undertaken at five times half-life after the first intake of the antiarrhythmic drug. Antiarrhythmic drug testing was performed according to a triple approach, consisting of long-term ambulatory ECG monitoring, bicycle exercise testing and programmed electrical stimulation. In the drug limb of the study, therapy failure of the first drug was accepted but failure of the second and different drug constituted the end of the study. In the surgical limb, map-guided arrhythmia surgery was carried out as soon as possible. If surgery failed, antiarrhythmic drugs were prescribed, but if two therapy failures in the drug limb occurred arrhythmia surgery was undertaken.
Clinical examination and follow-up
Non-invasive clinical examinations were undertaken with standard ECG, bicycle exercise testing, twochannel Holter recording, two-dimensional echocardiography and Doppler flow studies, and nuclear angiography. To determine eligibility for map-guided surgery and severity of coronary artery disease, standard right and left heart catheterization and coronary angiography were routinely applied in all patients after admission for ventricular tachycardia. For induction of ventricular tachyarrhythmias, programmed electrical stimulation was carried out according to standard procedures including delivery of one to three extra stimuli following a train of eight driven beats with increasing prematurity in the right ventricular apex or outflow, and incremental ventricular pacing with driven rates up to 200beats.min~'.
Prior to arrhythmia surgery, endocardial catheter activation sequence mapping of the left ventricle . Endocardial resection of the arrhythmogenic area, resection of the aneurysm and ventricular reshaping were done according to standard surgical procedures 1 ' 9 ' 201 . Before discharge, inducibility of ventricular tachycardia was tested with programmed electrical stimulation, using temporary epicardial wires'
.[211
After discharge, when results of antiarrhythmic drug testing were satisfactory, or following arrhythmic surgery, all patients were seen in follow-up at 3-to 6-months intervals. Patient compliance, side-effects of antiarrhythmic drugs, new arrhythmic or cardiovascular events were the major targets of these examinations. After documented or suspected recurrence of ventricular tachycardia, the patient was readmitted and studied according to the above protocol. Follow-up ended at therapy failure, death or end of the study.
Definitions
Failure of an antiarrhythmic drug was defined as: (1) documented spontaneous recurrence of ventricular tachycardia or ventricular fibrillation, irrespective of symptoms or sudden arrhythmic death; (2) inducibility of sustained ventricular tachycardia with programmed electrical stimulation of the heart with only one extra stimulus, independent of basic driven or spontaneous heart rate; (3) emergence of symptomatic non-sustained ventricular tachycardia (more than 10 successive ectopic beats) demanding antiarrhythmic drug; (4) side-effects or proarrhythmogenic effects demanding withdrawal.
Failure of arrhythmia surgery was defined as: (1) documented spontaneous recurrence of ventricular tachycardia or ventricular fibrillation, irrespective of symptoms or sudden arrhythmic death; (2) inducibility of sustained ventricular tachycardia with programmed electrical stimulation using identical criteria as for drug therapy; (3) emergence of symptomatic non-sustained ventricular tachycardia (more than 10 successive ectopic beats) demanding antiarrhythmic drug. Sudden cardiac death was defined as witnessed or unwitnessed death occurring within 1 h of the onset of symptoms.
Total cardiac death includes all cardiac causes of death.
Study end points
Primary end point: failure of two successive and different antiarrhythmic drugs in the drug limb, and failure of surgical treatment in the surgical limb. Secondary end point: total cardiac and sudden cardiac death in the drug and surgical limb.
Excluded patients
Patients not fulfilling intake criteria were followed by regular outpatients' visit, telephone interview or information from the local cardiologist. Type and change of arrhythmic treatment and time and cause of death were collected. However, this study did not permit systemic documentation of all non-fatal arrhythmic events of the excluded patients.
Statistical methods
Analysis was performed on the basis of intention to treat. All data are expressed as mean values ± 1 standard deviation or as proportions. Analysis of therapeutic failure and survival was performed by the Kaplan-Meier method and compared in both groups by the log-rank test. The standard errors of the survival proportions were computed using the normal approximation' 221 , in order to give an estimate of the variance, and not to calculate exact confidence intervals. In the univariate analysis, the effect of treatment is quantified by the risk ratio, defined as the ratio of two incidence rates by means of the Cox proportional hazard method. Multivariate analysis was performed using the Cox proportional hazard method. The 95% confidence intervals were calculated to indicate the precision of the risk ratio estimate. A P value <005 was considered statistically significant.
Results
Patient population and baseline characteristics
Between September 1987 and January 1993, 317 patients with at least one episode of symptomatic sustained ventricular tachycardia or ventricular fibrillation after acute myocardial infarction were admitted (Table 1) . Sixty-three of these patients (19-9%) fulfilling the inclusion criteria constituted the study population and were randomized for antiarrhythmic drug or surgical therapy after oral information and consent. Eighty-four patients were referred for arrhythmia work-up and the remainder were admitted. In both the drug (33 patients) and surgical limb (30 patients) anterior infarction with aneurysm was predominant, and the majority of the patients had 1-or 2-vessel disease ( Table 2 ). The degree of left ventricular dysfunction was equally distributed in both groups, as Eur Heart J. Vol. 17, April 1996 Downloaded from https://academic.oup.com/eurheartj/article-abstract/17/4/564/539685 by guest on 07 January 2019 reflected by a mean nuclear ejection fraction of 27% and 25%, and a mean wall motion score of 4-3 and 4-4 normal segments out of nine in the drug and surgical limb, respectively. The interval between remote myocardial infarction and first ventricular tachycardia was longer in the surgical group (mean 59 months) than in the medical group (mean 45 months) but this difference was not significant. The number of patients with out-ofhospital cardiac arrest, the number of failed antiarrhythmic drugs before randomization and the number of patients with previous amiodarone therapy did not significantly differ between the groups. Statistical analysis showed no difference in baseline characteristics in either group. In the majority of the patients (41 of 63 [65%]), the first spontaneous ventricular tachyarrhythmia after infarction was a monomorphic ventricular tachycardia, whereas ventricular fibrillation was the initial one recorded in 16 of 63 (25%) patients. In 10% of patients the pattern of the first spontaneous ventricular tachyarrhythmia and the related symptoms could not be traced. Before randomization, programmed electrical stimulation was performed in 59 of 63 (95%) patients, resulting in monomorphic sustained ventricular tachycardia in the majority (51 of 59 [86%]) of patients, whereas ventricular fibrillation following ventricular flutter was seen in only one patient. Although programmed electrical stimulation could not initiate sustained ventricular tachycardia in three patients, and programmed electrical stimulation was omitted in four other patients, they were not excluded because of previous recording of spontaneous sustained ventricular tachycardia.
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Surgical procedure
One patient died 2 days before scheduled surgery due to untractable ventricular tachycardia (Fig. 1 ). In the remaining 29 patients, after incision of the left ventricle, visual inspection of the endocardial surface showed the presence of endocardial fibrosis with an estimated mean of 298 ± 5-7%. In the majority of patients (59%), sustained ventricular tachycardia could be induced and, guided by endocardial mapping, in 11 of 29 (38%) patients, in whom the site of origin was unambiguous, a limited endocardial resection was done. In 18 (62%) patients, extensive resection of all visible scar tissue, including the delineated site of origin, was performed because pre-and intra-operative mapping findings were conflicting, or ventricular tachycardia induction failed. Left ventricular reshaping with the Dor technique 1201 was carried out in 24% of the patients, and in half of them pure aneurysmectomy without coronary bypass grafting was done. Coronary bypass grafting was performed in the other half of the patients, with a mean of 2-5 distal anastomoses. 
Therapy failure
Drug group Therapy failure became evident in 17 of 33 patients (51%) for the following reasons ( Fig. 1 ): spontaneous recurrence of ventricular tachycardia during the second antiarrhythmic drug regimen in 14 patients after a mean follow-up of 5-6 months after randomization, sudden cardiac death in two patients, and propafenone intoxication manifest by fatal cardiac arrest in one patient. In two cases, sudden cardiac death occurred after a follow-up of 25 and 28 months respectively. Ventricular tachycardia was not inducible with up to three extra stimuli in one patient treated with sotalol, but was inducible with two extra stimuli in the other patient treated with flecainide; this result was accepted according to our criteria. After a mean follow-up of 20 months, in 16 of 33 patients (48%) there was no therapy failure, 10 patients were still on the first drug regimen and six patients on the second drug regimen. One patient died from congestive heart failure without recurrence of ventricular tachycardia. The 14 patients with non-fatal therapy failure underwent arrhythmia surgery.
Surgical group
Therapy failure arose in 14 of 30 patients (47%) for the following reasons ( Fig. 1) : spontaneous ventricular tachycardia after surgery in four patients, ventricular tachycardia inducible with programmed electrical stimulation in four other patients, very symptomatic nonsustained ventricular tachycardia necessitating drug therapy in one patient, sudden cardiac death after discharge in four patients, one death from intractable ventricular tachycardia 2 days before scheduled arrhythmia surgery. The area of resected endocardial tissue expressed as limited or extensive, did not affect these results. In three of four patients, spontaneous sustained ventricular tachycardia recurred within 10 days of surgery, and in all the arrhythmia showed a new QRS morphology. Pre-discharge drug testing of propafenone or sotalol was satisfactory in two patients with spontaneous recurrence, whereas in the two remaining patients ventricular tachycardia could not be induced at follow-up even without drugs.
Four (13%) patients died suddenly after a mean follow-up of 17-9 months. Pre-discharge programmed electrical stimulation could not induce any ventricular arrhythmia in three of four patients, but in one patient ventricular tachycardia was induced with a QRS morphology very comparable to one of the pre-operatively induced ventricular tachycardias. Although the intraoperative mapping of two induced ventricular tachycardias showed sites of origin very comparable to two pre-operative catheter-mapped ventricular tachycardias, extensive endocardial resection was done. Because all studies were carried out under a very high amiodarone blood level (8-6 mg . 1 ~'), the patient was advised to undergo new programmed electrical stimulation 3 months after discharge, after washout of the amiodarone, but he refused further examinations. Unfortunately, 17 months later he was admitted after aborted sudden death, and died from brain damage. Sixteen of 30 (53%) patients remained free of therapy failure after a mean follow-up of 18 months after surgical procedure, including the three patients who died from heart failure ( Fig. 1) .
Eur Heart J, Vol. 17, April 1996 Figure 2 shows therapy failure over time in both limbs. The Kaplan-Meier 0-5-, 1-and 4-year proportion of patients with therapy failure in the drug limb was 39 ± 11%, 42 ± 11% and 51 ± 18%, respectively, and in the surgical limb 37 ±11%, 37 ±11%, and 50 ±20%, respectively, showing no statistical difference {P=0-82). The relative risk for therapy failure in patients treated with antiarrhythmic drugs was not higher than in operated patients (relative risk [RR] 0-92, CI 0-458-1 -87). Figure 3 shows survival in both therapeutic groups. The 1-and 4-year Kaplan-Meier proportion of surviving patients was 91 ± 6% and 78 ± 15% in the drug limb and 92 ± 6% and 59 ± 20% in the surgical limb, respectively, and showed no statistical difference (/>=()• 17).
Comparison of therapeutical strategies
Mortality
In the drug limb, two patients died from sudden cardiac death, one from congestive heart failure and another from propafenone intoxication -a total cardiac mortality of four out of 33 patients (12%) (Fig. 1) . In the surgical group, one patient died from drug-refractory ventricular tachycardia 2 days before scheduled surgery. There was no in-hospital mortality but four patients died from sudden cardiac death and three from congestive heart failure, resulting in a total cardiac mortality of eight out of 30 patients (27%) (Fig. 1) . Non-cardiac causes of death were absent in both groups. The relative risk for total cardiac death was twofold higher in the surgical group than in the drug group (RR 2-2 [CI 0-68-7-48]). Figure 4 shows freedom of sudden cardiac death in both groups. The 1-and 4-year Kaplan-Meier proportion of patients without this event was 100% and 85 ± 12% in the drug limb, and 95 ± 5% and 76 ± 18%, respectively, in the surgical limb, and did not demonstrate any difference (P=0-30). The relative risk for sudden cardiac death was twofold higher in the surgical group than in the drug group (RR 2-4 [CI 0-44-1301]).
Finally, multivariate analysis of baseline characteristics, such as age, gender, site of remote myocardial infarction, residual left ventricular function, number of narrowed coronary vessels, various time intervals and number of antiarrhythmic drugs or use of amiodarone prior to randomization, identified none of these factors as a predictor of therapeutic failure in either limb. Concerning total cardiac mortality, pre-randomization use of amiodarone only appeared to be a predictor (RR 413 [CI 1-24-13-80]), although the range of confidence interval undermines its validity. from this study. Cardiac surgery for symptomatic threevessel coronary artery disease or drug-refractory heart failure (21 1%), previous cardiac surgery (16-4%), inoperability due to poor residual left ventricular function (12-6%) or 'end stage' of drug therapy for postinfarction ventricular tachycardia demanding a definitive surgical solution (7-9%) were the major reasons for exclusion (Table 1) .
Excluded patients
In 168 of 254 (62-2%) excluded patients, the angiographic left ventricular wall motion score was determined and their follow-up was used for comparison. Fifty patients had a poor residual left ventricular function (<3 normal segments) whereas 118 patients had an acceptable or good one (^3 normal segments). Only cardiac cause of death were observed in the excluded patients. Figure 3 shows that the proportion of surviving excluded patients with ;>3 normal segments paralleled the surviving proportion of both study limbs, but the proportion of surviving patients was obviously smaller in the excluded group with <3 normal segments (P=0-007). The proportion of surviving excluded patients with ^3 normal segments was significantly larger than that of the excluded surviving patients with <3 normal segments (F=00001). Figure 4 also shows freedom from sudden cardiac death of excluded patients. The 1-and 4-year Kaplan-Meier freedom from sudden cardiac death in excluded patients with <3 or 5:3 normal segments was 77 ± 8% and 63 ± 30%, and 91 ± 3% and 88 ± 7%, respectively, and did not differ significantly between excluded groups with <3 or ^3 normal segments or between excluded and included groups (P=0-052).
Discussion
After the failure of one or more antiarrhythmic drugs to suppress sustained postinfarction ventricular tachycardia, it remains unclear whether continuation of drug therapy with new drug trials is superior to map-guided arrhythmia surgery. Therefore a randomized study comparing the therapeutic results of continued drug regimen and those of cardiac surgery was conducted in patients eligible for surgery. To the best of our knowledge this is the first randomized study evaluating both therapeutic modalities for postinfarction ventricular tachycardia. 
Results of this study
There was no clear difference in efficacy between continued drug therapy or arrhythmia surgery. The hazard of failure of antiarrhythmic drugs, such as sotalol, flecainide or propafenone, was most prominent in the first 6 months after starting drug therapy. During this interval, non-fatal and fatal drug failures occurred in 39% of the patients (Fig. 2) , whereas later there was only a small increase in the failure rate, resulting in drug failure in half of the patients at 4 years after randomization. These therapeutic results compare well with the long-term efficacy of today's potent antiarrhythmic drugs, such as amiodarone Comparable to drug therapy, the hazard of surgical failure to suppress ventricular tachycardia and to cause sudden cardiac death was most marked in the first 6 months after operation, as earlier reported 14 -51 (Fig. 2) . Because fatal and non-fatal recurrences occurred in 37% of the patients within the first postoperative half year, these events might reflect an insufficient intra-operative mapping technique or deficient surgical elimination of the arrhythmogenic substrate, or both. In addition, other causes, such as surgical damage to ventricular function, or a transient postoperative imbalance in the autonomic nervous system, unfavourably affecting remnants of the removed arrhythmogenic substrate or the residual ventricular tissue may have attributed to surgical failure 1251 . Diminishing levels of antiarrhythmic drugs, although withdrawn prior to surgery but still effective at post-surgical programmed electrical stimulation, may also have played a provocative role, as was documented in one late surgical fatality, pre-operatively treated with amiodarone. Multivariate analysis of baseline characteristics could not identify any predictor for therapy failure in either study limb.
Since it is almost impossible to perform mapguided surgery without some impairment of left ventricular function, one can anticipate less favourable survival in the surgical limb of this study. This was why surgery was compared with the administration of two different antiarrhythmic drugs, permitting the failure of at least one antiarrhythmic drug. Although the relative risk for total cardiac death, mostly intractable heart failure, was indeed 2-2 times higher in the surgical group than in the drug group, the Kaplan-Meier survival of both groups did not differ significantly (Fig. 3) . Factors meaningful to secure in-hospital and late survival were the strict application of selection criteria for surgery* number of cardiac surgeons involved in arrhythmia surgery in our institution, resulting in an accumulation of experience with this intervention, may also have contributed positively. The hazard for postoperative death, which in our series never occurred in hospital, was most marked in the first 6 months after surgery, as mentioned earlier (Fig. 3)' 4 ' 51 . The reasons given above for early recurrence of ventricular tachycardia after surgery probably also apply for early postoperative cardiac death.
The representativeness of the study population
To appreciate the results of this study, the clinical profile of the randomized patients needs clarification. For this purpose, the excluded patients with postinfarction ventricular tachycardia were compared with the included series of patients. Twenty percent of the 317 patients with postinfarction ventricular tachycardia were included during a recruitment period of almost 6 years (Table 1) . Two important reasons are responsible for this low recruitment rate: (1) the large number of patients with clear reasons for immediate or elective cardiac surgery, consisting of coronary revascularization for ischaemia-related arrhythmic events' 281 or arrhythmia surgery for additional reasons e.g. postinfarction ventricular tachycardia with severe angina; (2) inoperable arrhythmia due to severely impaired residual left ventricular function, concomitant diseases interfering with cardiac surgery, advanced age, or prerandomization in-hospital death (Table 1 ). In fact, during the recruitment period three times more patients underwent arrhythmia surgery for one of the above than the 30 patients randomized for surgery.
In view of the number of previous non-fatal drug failures (mean 30 in the drug group, 2-7 in the surgical group), observed over a mean of 4 years between latest acute myocardial infarction and time of randomization, a stable arrhythmogenic substrate was present in the majority of selected patients at time of randomization. Furthermore, comparison of the total cardiac death rate in included and excluded patients with 5:3 normal segments of the left ventricle showed no significant difference compared with excluded patients with <3 normal segments, in whom total cardiac mortality was much higher (Fig. 3) . Therefore, these findings characterize the randomized group of patients as a cohort of individuals with a reasonable cardiac life expectancy based on the residual left ventricular function 1 ' 3 ' 271 .
Limitations of the study
The number of study patients can be subject to criticism. However, one advantage of the study was uniformity of treatment protocol and surgical approach. An expansion of the study to other surgical centres in order to collect more patients in a shorter time frame might have unfavourably influenced the results due to interinstitutional differences. Furthermore, in view of the small differences in efficacy of both therapeutic limbs, 354 patients were to be included in the study limbs in the same recruitment period to obtain any statistical difference in outcome (a 005, power 0-80, difference in median survival at least 8 months). Even with the participation of other surgical centres this number of patients would not have been reached. Finally, the small number of included patients may invalidate the outcome of a multivariate analysis and the clinical implications.
Clinical implications
The comparable results of continuation of two different antiarrhythmic drugs, or arrhythmia surgery undertaken after multiple drug failures, give rise to the recommendation to proceed with other antiarrhythmic drugs until new drug failures or side-effects emerge. At this point, map-guided surgery should consequently be considered provided the residual left ventricular function fulfils selection criteria for surgery 1 ' 3|27] . However, when additional reasons for surgery exist, such as symptomatic multivessel coronary artery disease or drug-refractory heart failure requiring valve repair or aneurysmectomy with left ventricular reshaping, it is advisable to undertake arrhythmia surgery earlier after one or more drug failures.
Because map-guided arrhythmia surgery in eligible patients offers a potentially radical cure of ventricular arrhythmias and, when required, restoration of myocardial blood supply and reshaping of the infarcted left ventricle can be carried out simultaneously, cardiac surgery might be superior to implantations of a cardiac defibrillator. This device only suppresses ventricular tachycardia or ventricular fibrillation temporarily and does not affect the arrhythmogenic substrate at all 1291 . It is of interest to note that the 1-and 4-year KaplanMeier freedom from sudden cardiac death was 95 ± 5% and 76 ± 18%, respectively, in the surgically treated group (Fig. 4) , which is very competitive with the results with the implantable cardiodefibrillator in patients with postinfarction ventricular tachycardia and reasonable residual left ventricular function 130 " 321 . Finally, it is emphasized that the proposed recommendations resulting from this comparative study are neither applicable for patients with postinfarction ventricular tachycardia and a poor residual left ventricle (<3 normal segments) nor for patients with other reasons interfering with cardiac surgery.
